因塞特医疗(INCY)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

INCY 因塞特医疗

交易中 04-07 11:00:02 EDT

93.69

-1.17

-1.23%

最高95.07	最低93.29	成交量23.27万
今开94.43	昨收94.86	日振幅1.88%
总市值186.46亿	流通市值152.75亿	总股本1.99亿
成交额2,187万	换手率0.14%	流通股本1.63亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"INCY","market":"US","secType":"STK","nameCN":"因塞特医疗","latestPrice":93.69,"timestamp":1775574001550,"preClose":94.86,"halted":0,"volume":232738,"delay":0,"changeRate":-0.012333965844402295,"floatShares":163042517,"shares":199014486,"eps":6.41,"marketStatus":"交易中","change":-1.17,"latestTime":"04-07 11:00:02 EDT","open":94.43,"high":95.07,"low":93.29,"amount":21865675.75181,"amplitude":0.018764,"askPrice":93.75,"askSize":221,"bidPrice":93.62,"bidSize":126,"shortable":3,"etf":0,"ttmEps":6.41,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1775592000000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":94.86,"preHourTrading":{"tag":"盘前","latestPrice":94.8,"preClose":94.86,"latestTime":"09:18 EDT","volume":240,"amount":22649.359200000003,"timestamp":1775567898445,"change":-0.06,"changeRate":-0.000633,"amplitude":0.04445},"postHourTrading":{"tag":"盘后","latestPrice":95.52,"preClose":94.86,"latestTime":"19:16 EDT","volume":24861,"amount":2358584.19,"timestamp":1775517403717,"change":0.66,"changeRate":0.006958,"amplitude":0.006958},"volumeRatio":0.712336,"impliedVol":0.4346,"impliedVolPercentile":0.772},"requestUrl":"/m/hq/s/INCY","defaultTab":"news","newsList":[{"id":"1184093165","title":"Adagene与Incyte达成临床合作，评估Muzastotug (Adg126)联合Incyte的TgfßR2xPD-1双特异性抗体(Inca33890)用于微卫星稳定结直肠癌(MSS CRC)患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1184093165","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184093165?lang=zh_cn&edition=full","pubTime":"2026-04-02 19:02","pubTimestamp":1775127720,"startTime":"0","endTime":"0","summary":"Adagene宣布与Incyte达成临床合作，将共同评估Muzastotug (Adg126)与Incyte的TgfßR2xPD-1双特异性抗体(Inca33890)联合疗法在微卫星稳定结直肠癌(MSS CRC)患者中的疗效。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4139","INCY","BK4550","BK4532","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101340266","title":"因塞特医疗：Povorcitinib 54周总体安全性特征与既往数据一致，45毫克与75毫克剂量均耐受良好","url":"https://stock-news.laohu8.com/highlight/detail?id=1101340266","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101340266?lang=zh_cn&edition=full","pubTime":"2026-03-29 03:00","pubTimestamp":1774724430,"startTime":"0","endTime":"0","summary":"因塞特医疗公布的研究数据显示，Povorcitinib在长达54周的治疗期内，其总体安全性特征与先前报告的结果保持一致。无论是每日45毫克还是75毫克的给药剂量，均表现出良好的耐受性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BK4550","BK4588","BK4585","BK4139","INCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131957399","title":"因塞特医疗：Povorcitinib治疗在关键炎症性皮损类型中实现持续改善，高达20%患者达到完全消退","url":"https://stock-news.laohu8.com/highlight/detail?id=1131957399","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131957399?lang=zh_cn&edition=full","pubTime":"2026-03-29 03:00","pubTimestamp":1774724427,"startTime":"0","endTime":"0","summary":"因塞特医疗公布的研究数据显示，其候选药物Povorcitinib在针对多种关键炎症性皮损类型的治疗中展现出持续性的消退效果。值得注意的是，临床试验结果揭示，接受该治疗方案的患者群体中，实现皮损完全消退的比例最高可达20%。\n该研究通过系统评估不同形态的炎症性皮损变化，证实Povorcitinib能够同步改善各类关键病灶指标。分析指出，这种广谱疗效特征为患者提供了更全面的治疗选择，特别是对于复杂炎症性皮肤疾病的长期管理具有重要临床意义。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BK4588","BK4585","BK4550","INCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148003962","title":"骑士制药宣布Minjuvi®（Tafasitamab）在巴西获批新增适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=1148003962","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148003962?lang=zh_cn&edition=full","pubTime":"2026-03-17 19:32","pubTimestamp":1773747171,"startTime":"0","endTime":"0","summary":"骑士制药宣布，其产品Minjuvi®（Tafasitamab）在巴西监管机构批准下新增一项适应症。此次获批标志着该药物在巴西市场的应用范围进一步扩大，为相关患者群体提供了新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4550","INCY","BK4139","BK4532","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130476791","title":"Knight Therapeutics宣布在阿根廷和墨西哥提交Minjuvi®（Tafasitamab）用于滤泡性淋巴瘤的补充监管申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1130476791","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130476791?lang=zh_cn&edition=full","pubTime":"2026-03-17 19:31","pubTimestamp":1773747074,"startTime":"0","endTime":"0","summary":"Knight Therapeutics公司已正式向阿根廷和墨西哥的药品监管机构提交了Minjuvi®（Tafasitamab）用于治疗滤泡性淋巴瘤的补充注册申请。这一进展标志着该药物在拓展拉丁美洲市场方面迈出关键一步，为当地患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INCY","BK4532","BK4585","BK4588","BK4550","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618157119","title":"FDA 连发多份 CRL，开年大批新药上市申请已遭拒","url":"https://stock-news.laohu8.com/highlight/detail?id=2618157119","media":"制药网","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618157119?lang=zh_cn&edition=full","pubTime":"2026-03-11 14:39","pubTimestamp":1773211194,"startTime":"0","endTime":"0","summary":"2026年以来，全球医药企业就遭遇了FDA的CRL风暴。2月14日消息，Disc Medicine备受瞩目的候选药物Bitopertin用于治疗罕见血液病红细胞生成性卟啉症的上市申请遭到FDA拒绝。2月3日，阿斯利康公告称，美国FDA就Saphnelo用于成人系统性红斑狼疮患者皮下给药的生物制品许可申请发出完整答复函，驳回了其狼疮治疗药物的自行注射剂型上市申请。总的来说，2026 年 开年以来，已有众多新药上市申请被拒。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311144149a6b747a8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311144149a6b747a8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BFMHRM44.USD","LU0390134368.USD","LU1093756168.USD","AZN","BK4599","INCY","NVOX","LU0154236417.USD","BK4588","LU1093756325.SGD","BK4585","NVO","BK4007","BK4532","BK4530","NVOH","IE00BKVL7J92.USD","REGN","LU1815336091.USD","BK4121","LU0029874061.USD","LU0757428866.USD","IE00BZ1G4Q59.USD","LU0128526141.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142745804","title":"因塞特医疗宣布欧盟委员会批准Zynyz®（Retifanlimab）用于晚期肛管鳞状细胞癌一线治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1142745804","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142745804?lang=zh_cn&edition=full","pubTime":"2026-03-07 05:43","pubTimestamp":1772833392,"startTime":"0","endTime":"0","summary":"因塞特医疗（Incyte）近日宣布，其创新药物Zynyz®（Retifanlimab）已获得欧盟委员会批准，可作为晚期肛管鳞状细胞癌（SCAC）的一线治疗方案。这一批准标志着该免疫疗法正式进入欧洲市场，为患者提供了新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INCY","BK4550","BK4588","BK4139","BK4585","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107967568","title":"因塞特医疗高管透露：FDA一月告知公司，Opzelura需进行额外疗效研究方可获批结节性痒疹适应症","url":"https://stock-news.laohu8.com/highlight/detail?id=1107967568","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107967568?lang=zh_cn&edition=full","pubTime":"2026-02-10 21:32","pubTimestamp":1770730333,"startTime":"0","endTime":"0","summary":"因塞特医疗高管近日披露，美国食品药品监督管理局已于今年1月正式通知公司，其研发的Opzelura药物在获批用于治疗结节性痒疹之前，必须完成另一项疗效验证研究。这一要求意味着该药物针对此适应症的上市进程将面临新的监管审查环节。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BK4588","BK4585","INCY","BK4550","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1100720582","title":"因塞特高管表示：到2030年，剔除Jakafi后的核心业务规模有望达到当前Jakafi水平","url":"https://stock-news.laohu8.com/highlight/detail?id=1100720582","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100720582?lang=zh_cn&edition=full","pubTime":"2026-02-10 21:17","pubTimestamp":1770729421,"startTime":"0","endTime":"0","summary":"在最新电话会议中，因塞特医疗高层透露，公司旗下除明星产品Jakafi以外的核心业务管线展现出巨大增长潜力。该高管预测，若发展符合预期，这部分业务到2030年时有望达到与当前Jakafi同等规模的市场地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BK4139","BK4588","BK4585","INCY","BK4550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143730302","title":"异动解读 | 因塞特医疗盘前大跌近12%，2026年收入预期疲软加剧专利到期担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1143730302","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1143730302?lang=zh_cn&edition=full","pubTime":"2026-02-10 21:06","pubTimestamp":1770728817,"startTime":"0","endTime":"0","summary":"因塞特医疗（INCY）今日盘前股价大幅下挫11.95%，引发了市场广泛关注。消息面上，该公司发布了低于市场预期的2026年营收指引，预计在47.7亿至49.4亿美元之间，远低于分析师平均预期的55.2亿美元。同时，其寄予厚望的增长动力——皮肤病治疗药物Opzelura的2026年收入预期也低于分析师预估，这加剧了投资者对于公司能否在旗舰药物Jakafi专利于2028年到期后维持增长的担忧。尽管公司第四季度业绩表现强劲，总营收和Jakafi销售额均超预期，但疲软的前瞻性预测主导了市场情绪，导致股价在盘前交易时段遭遇重挫。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["INCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609070873","title":"华尔街顶级分析师最新评级：微软遭下调，Snap获上调","url":"https://stock-news.laohu8.com/highlight/detail?id=2609070873","media":"环球市场播报","labels":["rating"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609070873?lang=zh_cn&edition=full","pubTime":"2026-02-06 00:40","pubTimestamp":1770309654,"startTime":"0","endTime":"0","summary":"华尔街最受关注、能推动市场走势的研究报告现已汇总于此。以下由 The Fly 整理的今日投资者需重点关注的分析师评级调整。B． Riley：将 Snap评级从中性上调至买入，目标价维持10 美元不变。四季度财报发布后，该机构发现 Snap 多项核心举措已现积极进展，包括高端订阅收入持续强劲增长，以及高利润率广告形式的落地推广。美银：首次覆盖波泰科科学，给予买入评级，目标价38 美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-02-06/doc-inhkuyhz2645675.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"rating","news_rank":0,"length":0,"strategy_id":0,"source":"sina_us","symbols":["LU0823434740.USD","LU2236285917.USD","LU1334329650.SGD","LU0289960550.SGD","LU1267930490.SGD","LU2125154935.USD","SG9999014567.USD","SG9999015358.SGD","LU0006306889.USD","LU1629891620.HKD","IE00BJTD4V19.USD","LU2125909247.SGD","BK4543","IE0034235188.USD","LU0106261372.USD","LU0234572021.USD","LU2237443895.HKD","LU0256863902.USD","SG9999002232.USD","LU2237957902.USD","IE0004445239.USD","LU1196500208.SGD","IE0034235303.USD","LU0354030511.USD","LU1145028129.USD","LU0426417589.USD","LU0965508806.USD","LU1868836914.USD","LU0417517546.SGD","SG9999014880.SGD","LU2089284900.SGD","LU1074936037.SGD","LU1697837992.HKD","LU2505996681.GBP","IE000KEQY171.SGD","LU0345769631.USD","LU0265550359.USD","LU0310799852.SGD","LU0109391861.USD","LU0994945656.USD","IE00BSNM7G36.USD","LU0323591593.USD","LU2552382132.HKD","LU0476273544.USD","LU2063271972.USD","LU1235295455.SGD","LU0949170772.SGD","LU0316494557.USD","LU1670628061.USD","LU0175139822.USD","LU1244550577.SGD","LU2095319765.USD","LU0011850046.USD","LU2462157665.USD","LU0823417653.USD","LU2506952097.USD","LU1732800096.USD","LU1582986359.USD","BK4585","LU2764263203.CNY","LU1429558221.USD","LU2491050154.USD","IE00BBT3K403.USD","LU0215105999.USD","LU0985320562.USD","BK4588","IE00BQXX3F31.USD","LU1791710582.SGD","LU2211815571.USD","IE00BFSS7M15.SGD","LU2461242641.AUD","LU1037948897.HKD","LU2347655156.SGD","MSFX","LU0795875086.SGD","LU0879622024.SGD","LU1934455863.HKD","LU1923622614.USD","SGXZ51526630.SGD","LU1988902786.USD","LU1181866309.USD","LU2430703178.SGD","SGXZ31699556.SGD","LU0957791311.USD","LU1035773651.USD","LU1803068623.USD","LU0960925559.SGD","LU2271345857.HKD","LU1989772923.USD","LU2413666426.HKD","BK4534","SGXZ99366536.SGD","LU0708994859.HKD","LU2756315664.SGD","BK4548","SG9999014575.USD","LU0069063385.USD","LU0238689110.USD","LU1221951046.USD","LU0726765562.USD","LU2242649171.HKD","LU0965509010.AUD","LU2417539215.USD","LU2360108059.USD","IE0003U64NQ7.SGD","LU2764263039.SGD","LU2458330243.SGD","LU2471134796.USD","MSFW","LU0310800379.SGD","LU0124676726.USD","LU2023250330.USD","BK4551","LU2087625088.SGD","FUBO","IE00BZ1G4Q59.USD","CAVA","LU1221951129.SGD","LU2133065610.SGD","IE000ITXATA3.USD","LU0444971666.USD","SGXZ81514606.USD","BK4577","LU1718418525.SGD","LU0820562030.AUD","LU2362540622.SGD","BK4533","HK0000914686.HKD","LU1066051811.HKD","LU2362541513.USD","LU0511384066.AUD","IE00B3SWFQ91.USD","LU2471134879.HKD","LU2092937148.SGD","LU0154236417.USD","LU0345770308.USD","LU2361044865.SGD","IE00BYQQ9H92.USD","LU0784383803.USD","LU0965509283.SGD","LU2506951958.HKD","IE00B1BXHZ80.USD","LU1069344957.HKD","LU0690374961.EUR","BK4579","LU1732799900.SGD","IE0009G5SDU7.USD","LU1084165304.USD","LU0072461881.USD","DOCN","BK4097","SG9999014898.SGD","LU2168564065.EUR","LU2065171311.SGD","LU0234570918.USD","LU0345770993.USD","LU2404859741.USD","LU1852331112.SGD","GB00BDT5M118.USD","LU2298321311.HKD","LU0950375773.USD","LU0210528500.USD","LU0070217475.USD","LU2746668461.USD","LU0225283273.USD","LU0276348264.USD","LU1232071149.USD","LU1670627923.USD","IE00BK4W5L77.USD","LU1934455277.USD","SG9999000418.SGD","LU0345768153.USD","LU0345769128.USD","LU0267386448.USD","BK4538","IE00BYXW3230.USD","LU1066051498.USD","LU0823421416.USD","BK4587","LU1778281490.HKD","LU2092937221.SGD","LU0096364046.USD","MSFD","LU2357305700.SGD","LU2491049909.HKD","IE00BKVL7J92.USD","LU0557290698.USD","LU1868837300.USD","LU1989764664.SGD","LU2244417387.USD","LU1548497426.USD","BK4612","LU0308772762.SGD","LU0784384876.USD","LU0719512351.SGD","LU2420271590.USD","IE00B775SV38.USD","LU1064131342.USD","SG9999018865.SGD","LU1496350171.SGD","LU1582987597.SGD","MSFL","LU2237443978.SGD","LU2750360997.AUD","LU2065170008.USD","SG9999015978.USD","LU2237957811.SGD","LU1066051225.USD","LU0211327993.USD","LU2242650005.HKD","ANDE","LU0289739343.SGD","LU0894485498.HKD","LU2750360641.GBP","IE00BDCRKT87.USD","LU1116320901.HKD","LU2487616109.SGD","IE00BLSP4452.SGD","LU0061475181.USD","IE00B4YYXB79.USD","LU1989764748.USD","LU2250418816.HKD","LU0056508442.USD","LU1069347547.HKD","FUN","IE00B5TLWC47.USD","LU0251132253.USD","BK4581","LU1316542783.SGD","LU0077335932.USD","LU0390134368.USD","LU2168564222.USD","IE00B3S45H60.SGD","LU1642822529.SGD","LU2168563687.JPY","LU1116320737.USD","LU1571399168.USD","LU1280957306.USD","LU0738911758.USD","LU1032466523.USD","LU0158827948.USD","LU0545039389.USD","SGXZ23171101.USD","LU0072462426.USD","LU1228905037.USD","LU1043141396.HKD","LU1674673691.USD","LU0128525929.USD","LU0079474960.USD","LU1127390331.HKD","LU0256863811.USD","LU1121112475.USD","IE00BJTD4N35.SGD","LU1868837136.USD","LU2746668974.SGD","LU0057025933.USD","LU0096362180.USD","LU1496350502.SGD","LU0170899867.USD","LU0345774391.USD","LU2403377893.USD","LU1564329032.USD","LU2237438978.USD","LU1267930573.SGD","IE00B775H168.HKD","LU0788109477.HKD","LU0823417737.USD","LU2452424414.USD","LU1066053197.SGD","BK4527","LU1917777945.USD","LU2756315318.SGD","LU2247934214.USD","CPNG","LU2265009873.SGD","LU0820561909.HKD","LU0029864427.USD","LU2210150020.SGD","LU0882574139.USD","SG9999015945.SGD","BK4550","IE00B4JS1V06.HKD","LU1323610961.USD","IE00BKDWB100.SGD","BK4592","LU1989763005.USD","LU2552382058.USD","LU1934455194.USD","MSFT","LU1506573853.SGD","LU1974910355.USD","IE00BQXX3C00.GBP","LU0943347566.SGD","LU1815333072.USD","LU2362541273.HKD","BK4528","LU0784385840.USD","IE000W1ABFV2.USD","LU0757359954.USD","IE0009356076.USD","LU0949170426.SGD","LU0082616367.USD","GB00B4LPDJ14.GBP","LU1236620834.HKD","IE0004091025.USD","LU1839511570.USD","CE","LU1670711040.USD","LU0528227936.USD","LU0312595415.SGD","LU1815336760.USD","LU2552382215.SGD","LU2896262040.SGD","IE0034235295.USD","LU1153585028.USD","LU2237443549.SGD","LU1720051108.HKD","LU1261432733.SGD","LU2077746001.SGD","LU2191332357.HKD","IE00BMPRXQ63.HKD","IE00BLSP4239.USD","GB00B4QBRK32.GBP","LU2168564495.EUR","LU0342679015.USD","LU0171293334.USD","LU1035775433.USD","LU2860962120.EUR","LU1814569148.SGD","LU2083900584.USD","LU0345774631.USD","SNAP","LU2089283258.USD","LU0187121727.USD","LU1935042488.USD","IE00B19Z9505.USD","LU0289961442.SGD","CTVA","HK0000914660.USD","LU2106854487.HKD","LU1935042991.SGD","LU0792757196.USD","BK4566","LU0868494617.USD","LU1301847155.USD","LU0345768740.USD","LU0861579265.USD","LU1564329461.SGD","LU2505996509.AUD","MSFO","LU2264538146.SGD","BK4567","LU2097344357.USD","LU1235294995.USD","IE0004086264.USD","SG9999015986.USD","LU0795875169.SGD","LU1188199696.SGD","LU0080751232.USD","LU1003077747.HKD","LU2543165471.USD","LU2028103732.USD","LU0061474960.USD","LU2463028550.USD","LU0097036916.USD","LU0642271901.SGD","LU1670710588.SGD","LU1823568750.SGD","LU2237443622.USD","LU0894486033.HKD","LU1691799644.USD","LU1868836591.USD","LU0494093205.USD","LU1585245621.USD","LU1989772840.SGD","BK4535","LU0889566641.SGD","IE00B19Z8W00.USD","LU0158827781.USD","LU0545562505.USD","LU2360106780.USD","LU2210149790.SGD","LU0314106906.USD","LU0823421333.USD","BK4554","LU1267930730.SGD","IE00BN29S564.USD","LU1670711123.USD","WVE","LU0640476718.USD","ZM","LU1935042215.USD","LU0823434583.USD","LU2023250843.SGD","LU2125154778.USD","LU1430594728.SGD","LU0265550946.USD","LU1791710400.SGD","LU2471134952.CNY","IE000YTNTUN2.SGD","LU0048584097.USD","SG9999018857.SGD","LU2506951875.HKD","LU2506952170.USD","IE00BMPRXN33.USD","LU1674673428.USD","LU0672654240.SGD","LU2065169927.USD","LU2237443382.USD","LU0107464264.USD","LU0320765059.SGD","LU0912757837.SGD","LU2097829019.USD","LU2125909593.SGD","LU2279689827.SGD","IE00B19Z8X17.USD","LU2381873111.SGD","LU1435385759.SGD","LU0314104364.USD","SG9999001424.SGD","LU2602419157.SGD","LU2491050071.SGD","LU0724617625.USD","LU0426412945.USD","LU1366333091.USD","SG9999014906.USD","LU1914381329.SGD","LU0210533765.USD","LU2092627202.USD","LU1582986433.USD","LU2430703095.HKD","LU0466842654.USD","LU0289941410.SGD","IE00BJJMRX11.SGD","LU0162691827.USD","SG9999014559.SGD","INCY","LU2023251221.USD","LU2458330169.SGD","LU0787776722.HKD","LU1935043023.USD","LU1803068979.SGD","LU2430703251.USD","LU1551013425.SGD","LU0683600562.USD","BK4525","LU2065171402.SGD","IE00B5949003.HKD","LU0323239441.USD","IE0005OL40V9.USD","BK4503","LU1059921491.USD","BK4532","LU1551013342.USD","LU1720051017.SGD","LU0889565833.HKD","LU2404859667.USD","LU0871640123.AUD","LU1712237335.SGD","LU2592432038.USD","SHOO","LU1564329628.SGD","IE0004445015.USD","LU1119994496.HKD","LU1046421795.USD","LU2456880835.USD","LU2097344431.USD","LU1670710661.SGD","LU2360032135.SGD","LU2433249047.HKD","SG9999015341.SGD","LU0661504455.SGD","LU0354030438.USD","LU1366192091.USD","LU0347712357.USD","LU0081259029.USD","LU0964807845.USD","LU0109392836.USD","LU2023250504.SGD","LU0820561818.USD","LU0095938881.EUR","LU1868836757.USD","SG9999004303.SGD","IE00BN8TJ469.HKD","LU2471134523.USD","IE00BKPKM429.USD","SG9999001077.SGD","LU0689472784.USD","LU0965509101.SGD","LU2087621335.USD","BK4598","LU0348723411.USD","BK4504","LU2361044949.HKD","LU0957808578.USD","LU0456855351.SGD","LU1623119135.USD","LU2413666699.HKD","LU1037948541.HKD","IE00BFSS8Q28.SGD","IE00B7KXQ091.USD","LU0757359368.USD","LU1983260115.SGD","LU2168564149.EUR","IE00BFXG0V08.USD","LU0053666078.USD","LU2054465674.USD","IE00B1XK9C88.USD","LU0472753341.HKD","LU1564329115.USD","LU2213496289.HKD","LU2326559502.SGD","SG9999014542.SGD","LU1582987324.SGD","BK4516","LU0353189680.USD","SG9999002224.SGD","LU0149725797.USD","LU2286300806.USD","LU2111349929.HKD","LU0061474705.USD","LU0553294199.USD","LU1032955483.USD","IE00BK4W5M84.HKD","LU0690374615.EUR","LU1721428933.USD","LU0203201768.USD","LU0708995401.HKD","LU0211328371.USD","LU1236620750.USD","LU0127658192.USD","BK4508","IE00BHPRN162.USD","LU2347655073.USD","BK4077","LU0198837287.USD","IE00BJLML261.HKD","LU0210536198.USD","LU2237443465.HKD","LU1989773731.SGD","BK4576","IE00BDRTCR15.USD","SG9999015952.SGD","LU2764262908.HKD","IE00BJJMRY28.SGD","LU1340139317.AUD","LU1804176565.USD","LU1935043536.SGD","LU1244550221.USD","SG9999014914.USD","LU1633808545.USD","IE00BMPRXR70.SGD","LU0353189763.USD","LU0302445910.USD","LU0784385170.HKD","LU2361045086.USD","IE00BWXC8680.SGD","LU0203202063.USD","LU2041044095.USD","LU1267930813.SGD","LU0157215616.USD","LU2148611432.USD","LU0689626769.HKD","LU2275660780.HKD","LU2108987350.USD","IE0001KFT4U8.USD","IE00BQXX3D17.EUR","LU0323240290.USD","LU1043141123.HKD","LU2720916845.USD","LU1861127337.USD","LU0094547139.USD","MSFY","SG9999017495.SGD","LU1244550494.USD","LU0444973449.USD","LU1228905540.USD","LU0266013472.USD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1168517344","title":"因塞特医疗宣布Zynyz®获欧盟CHMP积极意见，用于晚期肛管鳞状细胞癌一线治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1168517344","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1168517344?lang=zh_cn&edition=full","pubTime":"2026-01-30 22:29","pubTimestamp":1769783353,"startTime":"0","endTime":"0","summary":"因塞特医疗近日宣布，其PD-1抑制剂Zynyz®获得欧盟人用药品委员会积极意见，支持该药物作为晚期肛管鳞状细胞癌的一线治疗方案。这一进展标志着Zynyz®在欧盟监管审批过程中迈出关键一步，若最终获批，将为该类罕见恶性肿瘤患者提供新的治疗选择。CHMP的积极意见基于临床研究数据，证实Zynyz®在延长患者生存期及改善生活质量方面的潜力。此次进展进一步巩固了因塞特医疗在肿瘤免疫治疗领域的创新地位。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4550","BK4139","BK4585","BK4532","INCY","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110439004","title":"因塞特医疗股价盘前涨2.8%，血癌疗法达晚期试验主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1110439004","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110439004?lang=zh_cn&edition=full","pubTime":"2026-01-05 20:53","pubTimestamp":1767617594,"startTime":"0","endTime":"0","summary":"因塞特医疗（Incyte）股价在盘前交易中上涨2.8%，此前该公司宣布其血癌疗法在晚期临床试验中达到了主要研究目标。这一积极进展提振了投资者信心，推动股价走高。\n该疗法在关键试验阶段的表现超出预期，为后续监管申请奠定了坚实基础。市场密切关注该疗法能否最终获批上市，从而为患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BK4588","BK4585","BK4139","INCY","BK4550"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146871643","title":"因塞特医疗计划于2026年上半年提交Tafasitamab一线治疗新诊断DLBCL成人患者的补充生物制剂许可申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1146871643","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146871643?lang=zh_cn&edition=full","pubTime":"2026-01-05 20:32","pubTimestamp":1767616336,"startTime":"0","endTime":"0","summary":"因塞特医疗宣布，公司预计将在2026年上半年为Tafasitamab提交一份补充生物制剂许可申请，旨在将其用于一线治疗新诊断的弥漫性大B细胞淋巴瘤成人患者。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","BK4550","INCY","BK4532","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112426504","title":"因塞特医疗公布Tafasitamab（Monjuvi®/Minjuvi®）作为弥漫性大B细胞淋巴瘤一线治疗关键研究的积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1112426504","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112426504?lang=zh_cn&edition=full","pubTime":"2026-01-05 20:30","pubTimestamp":1767616259,"startTime":"0","endTime":"0","summary":"因塞特医疗宣布，其关键临床研究取得积极顶线数据，评估Tafasitamab（商品名Monjuvi®/Minjuvi®）作为弥漫性大B细胞淋巴瘤（DLBCL）一线治疗方案的效果。该结果标志着该药物在早期治疗应用中的重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4550","BK4585","BK4532","BK4588","INCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178257358","title":"因塞特医疗在日本获批Zynyz®（Retifanlimab）用于晚期肛门癌的一线治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1178257358","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178257358?lang=zh_cn&edition=full","pubTime":"2025-12-22 15:46","pubTimestamp":1766389562,"startTime":"0","endTime":"0","summary":"因塞特医疗在日本获批Zynyz®（Retifanlimab）用于晚期肛门癌的一线治疗","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","INCY","BK4550","BK4585","BK4588","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119754749","title":"因塞特医疗宣布Minjuvi®（Tafasitamab）与利妥昔单抗及来那度胺联合用于治疗复发或难治性滤泡淋巴瘤获得批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1119754749","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119754749?lang=zh_cn&edition=full","pubTime":"2025-12-22 15:44","pubTimestamp":1766389475,"startTime":"0","endTime":"0","summary":"因塞特医疗宣布，Minjuvi®（Tafasitamab）与利妥昔单抗及来那度胺联合用于治疗复发或难治性滤泡淋巴瘤获得批准。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","BK4588","BK4585","BK4550","INCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2592155281","title":"AI狂欢过后如何备战2026？这四只“攻守兼备”的防御性股票值得关注","url":"https://stock-news.laohu8.com/highlight/detail?id=2592155281","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592155281?lang=zh_cn&edition=full","pubTime":"2025-12-19 15:05","pubTimestamp":1766127943,"startTime":"0","endTime":"0","summary":"如果2026年科技板块降温且经济增长保持温和而非强劲，这些公司可能成为当前值得买入的最佳防御性股票。收益率、通胀保护和盈利增长的结合，使该公司成为2026年防御性配置的基础性持仓。Iberdrola的基本面优势已转化为其在2025年表现动量方面的板块领先地位，这一势头在2026年有望延续。这些股票共同表明，防御性投资不一定枯燥或停滞不前，2026年最佳的防御性股票可能是那些既能保护资本，又能选择性实现资本增长的标的。","market":"us","thumbnail":"https://static.tigerbbs.com/e68f18a297e419bae3cc0320b6d8ff4e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/e68f18a297e419bae3cc0320b6d8ff4e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"85e8aafb51ba0ad706197d405ff70b96","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1383591.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"AI狂欢过后如何备战2026？这四只“攻守兼备”的防御性股票值得关注","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["INCY","VRTX","BRKR","IBDRY"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1177744150","title":"因塞特医疗宣布Minjuvi®（Tafasitamab）获欧洲委员会批准用于治疗复发性或难治性滤泡性淋巴瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=1177744150","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177744150?lang=zh_cn&edition=full","pubTime":"2025-12-18 00:21","pubTimestamp":1765988505,"startTime":"0","endTime":"0","summary":"因塞特医疗宣布Minjuvi®（Tafasitamab）获欧洲委员会批准用于治疗复发性或难治性滤泡性淋巴瘤","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4588","BK4585","BK4532","BK4550","INCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156411721","title":"因塞特医疗：HervÉ Hoppenot于12月10日通知即刻退休，辞去公司董事会职务","url":"https://stock-news.laohu8.com/highlight/detail?id=1156411721","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1156411721?lang=zh_cn&edition=full","pubTime":"2025-12-13 00:37","pubTimestamp":1765557437,"startTime":"0","endTime":"0","summary":"因塞特医疗：HervÉ Hoppenot于12月10日通知即刻退休，辞去公司董事会职务","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["INCY","BK4588","BK4139","BK4532","BK4550","BK4585"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.incyte.com;investor.incyte.com","stockEarnings":[{"period":"1week","weight":0.0501},{"period":"1month","weight":-0.0113},{"period":"3month","weight":-0.1106},{"period":"6month","weight":0.111},{"period":"1year","weight":0.5659},{"period":"ytd","weight":-0.0396}],"compareEarnings":[{"period":"1week","weight":0.0427},{"period":"1month","weight":-0.02},{"period":"3month","weight":-0.0475},{"period":"6month","weight":-0.0211},{"period":"1year","weight":0.3041},{"period":"ytd","weight":-0.0337}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"因塞特医疗公司于1991年在特拉华州注册成立。该公司是一家全球生物制药公司，从事专有疗法的发现、开发和商业化。其研究和商业努力集中在三个治疗领域：血液学、肿瘤学、炎症和自身免疫。","yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":0.084187},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.001443},{"month":3,"riseRate":0.424242,"avgChangeRate":-0.039602},{"month":4,"riseRate":0.484848,"avgChangeRate":-0.01062},{"month":5,"riseRate":0.625,"avgChangeRate":0.061854},{"month":6,"riseRate":0.59375,"avgChangeRate":0.024163},{"month":7,"riseRate":0.53125,"avgChangeRate":0.01586},{"month":8,"riseRate":0.53125,"avgChangeRate":0.019237},{"month":9,"riseRate":0.40625,"avgChangeRate":-0.019519},{"month":10,"riseRate":0.53125,"avgChangeRate":0.026823},{"month":11,"riseRate":0.59375,"avgChangeRate":0.061387},{"month":12,"riseRate":0.59375,"avgChangeRate":0.093713}],"exchange":"NASDAQ","name":"因塞特医疗","nameEN":"Incyte"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"因塞特医疗(INCY)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供因塞特医疗(INCY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"因塞特医疗,INCY,因塞特医疗股票,因塞特医疗股票老虎,因塞特医疗股票老虎国际,因塞特医疗行情,因塞特医疗股票行情,因塞特医疗股价,因塞特医疗股市,因塞特医疗股票价格,因塞特医疗股票交易,因塞特医疗股票购买,因塞特医疗股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"因塞特医疗(INCY)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供因塞特医疗(INCY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}